Latest Conference Articles

A post-hoc analysis of the AWARD-11 trial indicates that 4.5 mg of dulaglutide was effective in lowering and maintaining A1C levels <7% regardless of baseline levels.

Consideration of how immunotherapy may influence other allergic diseases, patient adherence options, and advancing assessment of peanut allergy options.

Surveyed patients discharged from the hospital are reporting respiratory burdens beyond 6 months. Are outpatient facilities equipped to manage COVID-19 long haulers?

A review of 3 new studies, which indicate the association between severe COVID-19 and the chronic disease is more intricate than previously thought.

From better education, to remote monitoring and consistent check-ins, clinicians may need to initiate better adherence in their younger, severely ill patients.

How dupilumab is observed to benefit EoE patients—and who may administer the biologic therapy.

An interview on the TSLP inhibitor's effect on exacerbations, hospitalizations, and disease progress over 52-week findings.

In data presented during AAAAI 21, researchers compared the 2006 and 2016 versions of the diagnostic criteria proposed by the NIAD/FAAN.

Perspective on how the interleukin-targeting biologic has unique benefit for the rare, under-resourced disease.

Oxygen saturation levels similar for both asthma patients and non-asthma patients following mask use.

Late-breaking data show allegic children as young as 1-4 years old may have sustained benefit from daily peanut protein exposure.

An interview with a Children's Hospital Colorado investigator on new remote-monitoring research into children's adherence trends.

Trials testing hydroxychloroquine against COVID-19 have produced mixed results.

The adjusted allergy prevalence in recent years was 2.6% in infants who have been introduced to peanuts at 12 months.

New survey results depict unexpected burdens in long-haul patients, as well as continued issues following rehabilitation.

Common positive effects includes help with sleep, less pain, and calming influence.

An interview with a study author on new interpretations of biologic asthma benefit.

A discussion on continued research into the first regulated treatment for pediatric peanut allergy.

Treatment showed a similar effect on patients with and without baseline asthma.

All patients in the study who tested positive for COVID-19 suffered from mild or moderate symptoms.

Researchers explore further endpoints from the SINUS-24 and SINUS-52 trials.

In data presented at AAAAI 2021, researchers present new data from the LIBERTY ASTHMA QUEST trial.

Dr. Matthew Brams presented new data showing the efficacy of CTx-1301 for ADHD.

CTx-1301's formulation enables 3 different doses within 1 pill for ADHD.

Researchers are prepared a phase 3 trial testing the treatment in adults with ADHD.

The role of many in psychiatry has changed during the COVID-19 pandemic.

Such scores could provide insight into the significant comorbidity rate of ADHD and other youth mood and emotional dysregulation issues.

Personalized, daily self-reporting for patients could influence future therapeutic strategies.

Investigators have observed a development-related shift in risks from teenaged ADHD and alcohol use risks in the patients' 30s.

A pair of researchers present plans to improve collaboration with other professionals in ADHD.